Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (MAZE), sold 30,000 shares at $48.20 ($1.5M) on 2026-03-20, disclosed to the SEC on 2026-03-20.
Scheduled sale ($1.5M) by President, R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.20 | 6,161 | $297K | 20.2% |
| 2 | $48.20 | 6,161 | $297K | 20.2% |
| 3 | $49.32 | 3,795 | $187K | 12.7% |
| 4 | $49.32 | 3,795 | $187K | 12.7% |
| 5 | $50.02 | 5,044 | $252K | 17.1% |
| 6 | $50.02 | 5,044 |
| $252K |
| 17.1% |
| Total | $49.10 avg | 30,000 | $1.5M | 100% |
| Filing → |
| MAZE | SELL | 2026-09-04 | $270K | — | Filing → |
| MAZE | SELL | 2026-09-03 | $426K | — | Filing → |
| MAZE | SELL | 2026-08-14 | $446K | — | Filing → |